Beijing, September 24, 2021 – The R&D-based Pharmaceutical Association Committee (RDPAC) announces a great news on its newly-elected Executive Committee Members for 2022-2023 today. The election was conducted among all GMs of RDPAC member companies starting from September 7, 2021. Forty-one (41) valid votes have been received and 13 General Managers were elected as RDPAC Executive Committee Members, with service term of Year 2022 to 2023.
The new Executive Committee Members are:
On behalf of all the member companies, RDPAC Office would express our big congrats to each and every one of the EC-Elect members for winning the election! We look very much forward to working with them under their leadership, together with each of the GMs and their teams of all the member companies of RDPAC.
The new RDPAC Executive Committee will spearhead various work streams of the Association. With their support and guidance, the RDPAC member companies will continuously provide high-quality and innovative healthcare products and services to the Chinese patients, support the development of a sustainable ecosystem for drug innovation in China. Together, the Industry is committed to be a valued partner in delivering the “Healthy China 2030” goal to improve the health and quality of life of the people in China.
As the next step, RDPAC will facilitate the election for the EC Chairman and 2 Vice Chairmen in the coming weeks. We will keep you informed of the results, upon which the whole election process will be closed on around Oct.20th.
